

Dementia (Central Nervous System) - Drugs In Development, 2021

https://marketpublishers.com/r/D2B2DB3E295CEN.html

Date: June 2021 Pages: 682 Price: US\$ 2,500.00 (Single User License) ID: D2B2DB3E295CEN

Abstracts

Dementia (Central Nervous System) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia (Central Nervous System) - Drugs In Development, 2021, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person's daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia (Central Nervous System) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and



discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 13, 35, 31, 2, 79, 41 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 13, 5 and 1 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.



The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.





Contents

Introduction Dementia - Overview Dementia - Therapeutics Development Dementia - Therapeutics Assessment Dementia - Companies Involved in Therapeutics Development Dementia - Drug Profiles Dementia - Dormant Projects Dementia - Discontinued Products Dementia - Product Development Milestones Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Dementia, 2021 Number of Products under Development by Companies, 2021 Number of Products under Development by Universities/Institutes, 2021 Products under Development by Companies, 2021 Products under Development by Universities/Institutes, 2021 Number of Products by Stage and Target, 2021 Number of Products by Stage and Mechanism of Action, 2021 Number of Products by Stage and Route of Administration, 2021 Number of Products by Stage and Molecule Type, 2021 Dementia - Pipeline by AbbVie Inc, 2021 Dementia - Pipeline by Acadia Pharmaceuticals Inc, 2021 Dementia - Pipeline by Actinogen Medical Ltd, 2021 Dementia - Pipeline by AcuraStem Inc, 2021 Dementia - Pipeline by Adamed Sp zoo, 2021 Dementia - Pipeline by ADEL Inc, 2021 Dementia - Pipeline by AFFiRiS AG, 2021 Dementia - Pipeline by AgeneBio Inc, 2021 Dementia - Pipeline by AIBIOS Co Ltd, 2021 Dementia - Pipeline by Alector Inc, 2021 Dementia - Pipeline by Alkermes Plc, 2021 Dementia - Pipeline by AlphaCognition Inc, 2021 Dementia - Pipeline by Alterity Therapeutics Ltd, 2021 Dementia - Pipeline by Amarantus Bioscience Holdings Inc, 2021 Dementia - Pipeline by Anavex Life Sciences Corp, 2021 Dementia - Pipeline by Annovis Bio Inc, 2021 Dementia - Pipeline by Aphios Corp, 2021 Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, 2021 Dementia - Pipeline by Yumanity Therapeutics Inc, 2021 Dementia - Dormant Projects, 2021 Dementia - Discontinued Products, 2021



List Of Figures

LIST OF FIGURES

Number of Products under Development for Dementia, 2021 Number of Products under Development by Companies, 2021 Number of Products under Development by Universities/Institutes, 2021 Number of Products by Top 10 Targets, 2021 Number of Products by Stage and Top 10 Targets, 2021 Number of Products by Top 10 Mechanism of Actions, 2021 Number of Products by Stage and Top 10 Mechanism of Actions, 2021 Number of Products by Top 10 Routes of Administration, 2021 Number of Products by Stage and Top 10 Routes of Administration, 2021 Number of Products by Stage and Top 10 Routes of Administration, 2021 Number of Products by Stage and Top 10 Routes of Administration, 2021 Number of Products by Stage and Top 10 Molecule Types, 2021



I would like to order

Product name: Dementia (Central Nervous System) - Drugs In Development, 2021 Product link: <u>https://marketpublishers.com/r/D2B2DB3E295CEN.html</u> Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service: info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/D2B2DB3E295CEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970